Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Parra

Showing results (31-40 of 254) with videos related to

Pageof 26
Sort By:
American Journal of Clinical Pathology|April 29, 2016
IFITM1 Is Superior to CD10 as a Marker of Endometrial Stroma in the Evaluation of Myometrial Invasion by Endometrioid AdenocarcinomaAurelia Busca, Bojana Djordjevic, Ana Giassi, et al.
Histopathology|May 8, 2021
Ovarian mucinous and seromucinous neoplasms: problematic aspects and modern diagnostic approachKaren L Talia, Carlos Parra-Herran, W Glenn McCluggage
Journal of Clinical Pathology|February 19, 2024
Macroscopic examination of gynaecological specimens: a critial and often underemphasised aspect of pathological reportingKaren L Talia, Carlos Parra-Herran, W Glenn McCluggage
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|July 13, 2017
IFITM1 Outperforms CD10 in Differentiating Low-grade Endometrial Stromal Sarcomas From Smooth Muscle Neoplasms of the UterusAurelia Busca, Previn Gulavita, Carlos Parra-Herran, et al.
Histopathology|February 15, 2024
Diagnosis of verruciform acanthotic vulvar intra-epithelial neoplasia (vaVIN) using CK17, SOX2 and GATA3 immunohistochemistryEleanor Cook, Koen Van de Vijver, Carlos Parra-Herran
Journal of Medical Economics|April 28, 2026
Subcutaneous foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson's disease (aPD): societal cost impact analysis for the UK, France, Germany, Spain, and CanadaK Ray Chaudhuri, Juan Carlos Parra, Trishal Boodhna, et al.
Pathology Oncology Research : POR|July 24, 2012
Pelvic angiosarcoma occurring in a postmenopausal female: case report and review of the literatureJorge Villaran, Arturo Loaiza-Bonilla, Carlos Parra-Herran, et al.
Journal of Agricultural and Food Chemistry|February 24, 2024
Mathematical Modeling of Alpha-Tocopherol Early Degradation Kinetics to Predict the Shelf-Life of Bulk OilsIpek Bayram, Carlos Parra-Escudero, Eric A Decker, et al.
Vaccines|July 29, 2023
Usefulness of Docking and Molecular Dynamics in Selecting Tumor Neoantigens to Design Personalized Cancer Vaccines: A Proof of ConceptDiego Amaya-Ramirez, Laura Camila Martinez-Enriquez, Carlos Parra-López
Critical Reviews in Oncology/Hematology|May 11, 2024
A review concerning the breast cancer-related tumour microenvironmentOscar Hernán Rodríguez-Bejarano, Carlos Parra-López, Manuel Alfonso Patarroyo
Pageof 26

Showing results (31-40 of 254) with videos related to

Sort By:
Pageof 26
American Journal of Clinical Pathology|April 29, 2016
IFITM1 Is Superior to CD10 as a Marker of Endometrial Stroma in the Evaluation of Myometrial Invasion by Endometrioid AdenocarcinomaAurelia Busca, Bojana Djordjevic, Ana Giassi, et al.
Histopathology|May 8, 2021
Ovarian mucinous and seromucinous neoplasms: problematic aspects and modern diagnostic approachKaren L Talia, Carlos Parra-Herran, W Glenn McCluggage
Journal of Clinical Pathology|February 19, 2024
Macroscopic examination of gynaecological specimens: a critial and often underemphasised aspect of pathological reportingKaren L Talia, Carlos Parra-Herran, W Glenn McCluggage
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|July 13, 2017
IFITM1 Outperforms CD10 in Differentiating Low-grade Endometrial Stromal Sarcomas From Smooth Muscle Neoplasms of the UterusAurelia Busca, Previn Gulavita, Carlos Parra-Herran, et al.
Histopathology|February 15, 2024
Diagnosis of verruciform acanthotic vulvar intra-epithelial neoplasia (vaVIN) using CK17, SOX2 and GATA3 immunohistochemistryEleanor Cook, Koen Van de Vijver, Carlos Parra-Herran
Journal of Medical Economics|April 28, 2026
Subcutaneous foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson's disease (aPD): societal cost impact analysis for the UK, France, Germany, Spain, and CanadaK Ray Chaudhuri, Juan Carlos Parra, Trishal Boodhna, et al.
Pathology Oncology Research : POR|July 24, 2012
Pelvic angiosarcoma occurring in a postmenopausal female: case report and review of the literatureJorge Villaran, Arturo Loaiza-Bonilla, Carlos Parra-Herran, et al.
Journal of Agricultural and Food Chemistry|February 24, 2024
Mathematical Modeling of Alpha-Tocopherol Early Degradation Kinetics to Predict the Shelf-Life of Bulk OilsIpek Bayram, Carlos Parra-Escudero, Eric A Decker, et al.
Vaccines|July 29, 2023
Usefulness of Docking and Molecular Dynamics in Selecting Tumor Neoantigens to Design Personalized Cancer Vaccines: A Proof of ConceptDiego Amaya-Ramirez, Laura Camila Martinez-Enriquez, Carlos Parra-López
Critical Reviews in Oncology/Hematology|May 11, 2024
A review concerning the breast cancer-related tumour microenvironmentOscar Hernán Rodríguez-Bejarano, Carlos Parra-López, Manuel Alfonso Patarroyo
Pageof 26